Literature DB >> 242209

Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension.

F R Bühler, F Burkart, B E Lütold, M Küng, G Marbet, M Pfisterer.   

Abstract

Three hundred fifteen patients with essential hypertension were classified according to low (18 percent), normal (59 percent) or high (23 percent) renin-sodium index. The proportion of patients with low renin hypertension progressively increased with increasing age and blood pressure, there being no difference between the sexes. Two high renin groups emerged: a younger group with early moderate hypertension, and an older group with severe hypertension consequent to possibly ischemic renal disease. Long-term beta blocking monotherapy in 137 patients resulted in a reduction of idastolic pressure to 95 mm Hg or less in 65 percent: 85 percent in those with high and 73 percent in those with normal renin activity; pressure was reduced to this level in only 1 of 24 patients (4 percent) with a low renin index. Antihypertensive efficacy was also related to age, since diastolic pressure was normalized in 80 percent of patients under age 40 years, in 50 percent of those aged 40 to 60 years, but in only 20 percent of those over age 60 years. Age may heolp in patient selection but is no substitute for the more reliable renin index, especially in patients over age 40 years, or with high pressure. Using studiew with propranolol as a standard, similar renin responses were obtained with two cardioselective beta1 type blocking drugs, atenolol and metoprolol, as well as with two nonselective beta2+1 receptor antagonists, LL21945 exhibiting prolonged receptor affinity and oxprenolol in slow release form. These long-acting drugs, which proved effective in single daily doses, could be of value in improving patient compliance...

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 242209     DOI: 10.1016/0002-9149(75)90168-x

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  55 in total

Review 1.  Matching the right drug to the right patient in essential hypertension.

Authors:  M J Brown
Journal:  Heart       Date:  2001-07       Impact factor: 5.994

2.  Assessment of alpha- and beta-adrenoceptor blocking actions of labetalol.

Authors:  D A Richards; J Tuckman; B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

3.  Effects of salbutamol and metoprolol on plasma renin activity and plasma potassium of normal subjects and of hypertensive patients.

Authors:  A Salvetti; L Poli; F Arzilli; L Sassano; R Pedrinelli; M Motolese
Journal:  J Endocrinol Invest       Date:  1978-01       Impact factor: 4.256

4.  Steady state pharmacokinetics of hydrolysed bopindolol in young and elderly men.

Authors:  D Holmes; E Nuesch; J M Houle; J Rosenthaler
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 5.  Age-related changes in autonomic control: the use of beta blockers in the treatment of hypertension.

Authors:  K J Collins
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

Review 6.  Required beta blocker profile in the elderly.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1991-01       Impact factor: 3.727

Review 7.  The rush to adrenaline: drugs in sport acting on the beta-adrenergic system.

Authors:  E Davis; R Loiacono; R J Summers
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

8.  Management of more severe cases of hypertension.

Authors:  H Mandin
Journal:  Can Fam Physician       Date:  1985-02       Impact factor: 3.275

9.  Lead-induced hypertension: blunted beta-adrenoceptor-mediated functions.

Authors:  O Bertel; F R Bühler; J Ott
Journal:  Br Med J       Date:  1978-03-04

Review 10.  Acebutolol. A review of its pharmacological properties and therapeutic efficacy in hypertension, angina pectoris and arrhythmia.

Authors:  B N Singh; W R Thoden; A Ward
Journal:  Drugs       Date:  1985-06       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.